PWM
ACAD icon

Prentice Wealth Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Prentice Wealth Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-227
Closed -$4K – 103
2021
Q3 		$4K Hold
227
– – ﹤0.01% 283
2021
Q2 		$6K Sell
227
-10
-4% -$226 ﹤0.01% 260
2021
Q1 		$6K Buy
+237
New +$10.4K ﹤0.01% 262

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Prentice Wealth Management's ACAD Position: Q4 2021 in Review

Prentice Wealth Management sold out of Acadia Pharmaceuticals (ACAD) in Q4 2021, closing a stake of 227 shares — an estimated $4K sold.

Prentice Wealth Management first reported a position in ACAD in Q1 2021 and held it in 3 quarters. The position peaked at $6K in Q2 2021. 247 funds tracked by Wall St. Rank hold ACAD as of Q4 2021.

  • Prentice Wealth Management reported no remaining Acadia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Prentice Wealth Management sold 227 Acadia Pharmaceuticals shares in Q4 2021, an estimated $4K.
  • Prentice Wealth Management first reported a position in Acadia Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Prentice Wealth Management's Acadia Pharmaceuticals position peaked at $6K in Q2 2021.
  • 247 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2021.

Based on Prentice Wealth Management's 13F filing for Q4 2021, filed 31 Oct 2022.